• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Tykerb

On January 29, 2010, the U.S. Food and Drug Administration granted accelerated approval to lapatinib tablets (Tykerb, GlaxoSmithKline) for use in combination with letrozole (Femara, Novartis Pharmaceuticals Corp.) for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is indicated.  Lapatinib, in combination with an aromatase inhibitor, has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.  The approval was based on a clinically meaningful increase in progression-free survival (PFS) observed in a single trial (EGF30008).  As a condition of accelerated approval, subsequent randomized trials are required to verify and describe the clinical benefit of lapatinib in patients with metastatic breast cancer who have received prior treatment with trastuzumab.

 

EGF30008 was multinational, randomized, placebo-controlled trial of lapatinib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive metastatic breast cancer who had not received prior therapy for metastatic disease.  Patients were randomly assigned to receive lapatinib (1,500 mg once daily) plus letrozole (2.5 mg once daily) or to placebo plus letrozole (2.5 mg once daily).  There were 219 patients (17%) who were HER2-positive, 952 (74%) patients who were HER2-negative, and 115 (9%) patients did not have their HER2-receptor status confirmed.

Accelerated approval was based on the results from the group of postmenopausal women with metastatic breast cancer that overexpressed the HER2 receptor.  The primary efficacy endpoint was PFS, defined as the time interval between randomization date and the date of either first documented disease progression or death due to any cause.  The lapatinib plus letrozole combination had a median PFS of 35.4 weeks compared to 13.0 weeks for the placebo plus letrozole arm (HR = 0.71,  p = 0.019). The overall survival data are not mature at this time.

Safety data was evaluated in 1278 postmenopausal women with hormone receptor-positive metastatic breast cancer.  The safety profile of lapatinib in this trial population was consistent with previous safety data.  The most common adverse reactions (≥10%) in the lapatinib plus letrozole arm were diarrhea, rash, nausea, and fatigue.  Elevated liver enzymes and bilirubin were reported in 53% and 22% of the patients receiving lapatinib, respectively. Among 654 patients who received the lapatinib plus letrozole treatment, 26 patients experienced Grade 1 or 2, and 6 patients experienced Grade 3 or 4 decreases in left ventricular ejection fraction.

Full prescribing information, including clinical trial information, safety, dosing, drug-drug interactions and contraindications is available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf